Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 23Pancreatic Neoplasms 10Stomach Neoplasms 9Colonic Neoplasms 8Esophageal Neoplasms 7Neoplasm Metastasis 6Adenocarcinoma Of Esophagus 6Urinary Bladder Neoplasms 5Rectal Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Squamous Cell Carcinoma of Head and Neck 4Cholangiocarcinoma 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Ovarian Neoplasms 3Neoplasms 3Endometrial Neoplasms 3Adenocarcinoma 3Uterine Cervical Neoplasms 2Melanoma 2Lung Neoplasms 2Gastrointestinal Neoplasms 2Carcinoma, Hepatocellular 2Biliary Tract Neoplasms 2Urothelial Carcinoma of the Bladder 1Triple Negative Breast Neoplasms 1Tongue Neoplasms 1Thyroid Neoplasms 1Solid Tumors 1Small Bowel Adenocarcinoma 1Sarcoma, Ewing 1

Interventions

Bevacizumab 2repotrectinib 1Oviposition 1Leucovorin 1Irinotecan 1Fluorouracil 1Drug Therapy 1Drainage 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Intestinal Neoplasms × Fluorouracil × 30 days × Clear all
NCT03303495 2026-06-05

A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC

Sun Yat-sen University

Phase 3 Recruiting
280 enrolled
Gastrointestinal

Digestive System Neoplasms, Gastrointestinal Neoplasms, Intestinal Neoplasms, Neoplasm Metastasis, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡